Maypharm Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 04-07-2024
- Paid Up Capital ₹ 0.20 M
as on 04-07-2024
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 924.68%
(FY 2023)
- Profit 80.88%
(FY 2023)
- Ebitda 99.61%
(FY 2023)
- Net Worth -10.02%
(FY 2023)
- Total Assets 41.37%
(FY 2023)
About Maypharm Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Jaynil Doshi, Vijay Doshi, Ameya Budukh, and One other member serve as directors at the Company.
- CIN/LLPIN
U51101MH2016PTC273231
- Company No.
273231
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Feb 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai City, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Maypharm Lifesciences Private Limited offer?
Maypharm Lifesciences Private Limited offers a wide range of products and services, including Marketing Services & Consultants, Marketing Services, Architectural & Civil Engineering, Architectural Services, Business Planning and Management, Business Consultant, Software Development & IT Consultant, Software Development Services.
Who are the key members and board of directors at Maypharm Lifesciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sameer Kolhe  | Managing Director | 17-Feb-2016 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vijay Doshi | Director | 06-Aug-2019 | Current |
| Jaynil Doshi | Director | 06-Aug-2019 | Current |
| Ameya Budukh | Director | 26-Dec-2017 | Current |
Financial Performance of Maypharm Lifesciences.
Maypharm Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 924.68% increase. The company also saw a substantial improvement in profitability, with a 80.88% increase in profit. The company's net worth observed a substantial decline by a decrease of 10.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Maypharm Lifesciences?
In 2017, Maypharm Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Zalika Pharmaceuticals Private LimitedActive 6 years 7 months
Ameya Budukh and Sameer Kolhe are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Maypharm Lifesciences?
Unlock and access historical data on people associated with Maypharm Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maypharm Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maypharm Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
